^Ma, Yuzhong; Karuna Sachdeva; Jirong Liu1; Michael Ford; Dongfang Yang; Ikhlas Khan; Clinton Chichester; Bingfang Yan (November 2004). “Desmethoxyyangonin and dihydromethysticin are two major pharmacological kavalactones with marked activity on the induction of CYP3A23.”. Drug Metabolism and Disposition32 (11): 1317-1324. doi:10.1124/dmd.104.000786. PMID15282211.
^“Effects of kawain and dihydromethysticin on field potential changes in the hippocampus.”. Progress in Neuro-psychopharmacology and Biological Psychiatry21 (4): 697-706. (May 1997). doi:10.1016/s0278-5846(97)00042-0. PMID9194150.
^Sarris, Jerome; Laporte, Emma; Schweitzer, Isaac (2011). “Kava: A Comprehensive Review of Efficacy, Safety, and Psychopharmacology”. Australian & New Zealand Journal of Psychiatry45 (1): 27-35. doi:10.3109/00048674.2010.522554. PMID21073405.